Clinical trial · Interventional
Promoting Informed Choice for Breast Cancer Screening: A Longitudinal Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
All participants will read a decision aid (DA) communicating evidence about mammography screening benefits and harms. Participants' evaluations of that evidence will be assessed, along with their screening intentions and receipt of screening. Participants will be sent 3 surveys via email and a final brief survey conducted by email or phone. The four surveys will be collected 1) upon enrollment and prior to the primary care appointment; 2) following the primary care appointment; 3) 3 months after enrollment; 4) 1 year after enrollment. The final 2 surveys will offer an increased incentive to increase retention rates.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| REDS survey | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Cohort-1
- description
- Individuals who identify as female at birth age 39-49 without a prior breast cancer diagnosis (including DCIS or LCIS) or known BCRA1/2 gene mutations.
- interventionNames
- Behavioral: REDS survey
Primary outcomes (3)
- measure
- REDS (Reactance, Self-Exemption, Disbelief and Source Derogation) Reactions to Mammography Benefits
- timeFrame
- 12 months
- description
- Reactance, self-Exemption, Disbelief and Source derogation in reaction to evidence about mammography benefits. This is a multi-item measure (3-4 questions per subscale) and assessed on a 1 (strongly disagree) to 5 (strongly agree) Likert scale. Averages will be computed to create for scores (corresponding to each sub scale), with a maximum score of 5 and minimum score of 1. Higher scores indicate more reactance, self-exemption and disbelief.
- measure
- Screening Intentions Question
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 39 Years
- Maximum age
- 49 Years
Show eligibility criteria text
Inclusion Criteria: * Individuals who identify as female at birth * Ages 39-49 years old (inclusive) at the time of consent * English literacy * Internet access * No prior diagnosis of breast cancer, ductal carcinoma in situ (DCIS, also known as "stage zero breast cancer"), or lobular carcinoma in situ * No known BCRA1/2 gene mutation Exclusion Criteria: * Individuals who identify other than female at birth * Individuals who are currently pregnant * Individuals \< 39 years old or 50 years old and \> at the time of consent * Lack English literacy * Lack of internet access * Prior diagnosis of breast cancer, ductal carcinoma in situ (DCIS, also known as "stage zero breast cancer"), or lobular carcinoma in situ * Known BCRA1/2 gene mutation * Decisionally Challenged Individuals * Prisoners or those on alternative sentencing or probation
References
Publications (0)
Data not yet available